53 related articles for article (PubMed ID: 21323891)
21. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
22. CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B-cell apoptosis.
Khine AA; Firtel M; Lingwood CA
J Cell Physiol; 1998 Aug; 176(2):281-92. PubMed ID: 9648915
[TBL] [Abstract][Full Text] [Related]
23. Lack of expression of the chondroitin sulphate proteoglycan neuron-glial antigen 2 on candidate stem cell populations in paediatric acute myeloid leukaemia/abn(11q23) and acute lymphoblastic leukaemia/t(4;11).
Neudenberger J; Hotfilder M; Rosemann A; Langebrake C; Reinhardt D; Pieters R; Schrauder A; Schrappe M; Röttgers S; Harbott J; Vormoor J
Br J Haematol; 2006 May; 133(3):337-44. PubMed ID: 16643437
[TBL] [Abstract][Full Text] [Related]
24. Expression of B cell-associated transcription factors in B-cell precursor acute lymphoblastic leukemia cells: association with PU.1 expression, phenotype, and immunogenotype.
Nishii K; Kita K; Miwa H; Shikami M; Taniguchi M; Usui E; Katayama N; Shiku H
Int J Hematol; 2000 Jun; 71(4):372-8. PubMed ID: 10905058
[TBL] [Abstract][Full Text] [Related]
25. Characterization of porcine CD19 and anti-CD19 monoclonal antibodies.
Sun J; Sinkora J; Wertz N; Moravkova A; Butler JE
Mol Immunol; 2004 Jul; 41(9):929-38. PubMed ID: 15261465
[TBL] [Abstract][Full Text] [Related]
26. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+CD19- cells.
Hotfilder M; Röttgers S; Rosemann A; Schrauder A; Schrappe M; Pieters R; Jürgens H; Harbott J; Vormoor J
Cancer Res; 2005 Feb; 65(4):1442-9. PubMed ID: 15735032
[TBL] [Abstract][Full Text] [Related]
27. CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia.
Krishnan V; Xu X; Kelly D; Snook A; Waldman SA; Mason RW; Jia X; Rajasekaran AK
Mol Pharm; 2015 Jun; 12(6):2101-11. PubMed ID: 25898125
[TBL] [Abstract][Full Text] [Related]
28. Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed-CD19 selective pressure.
Lucero OM; Parker K; Funk T; Dunlap J; Press R; Gardner RA; Chang BH
Br J Haematol; 2019 Jul; 186(2):333-336. PubMed ID: 30810217
[No Abstract] [Full Text] [Related]
29. Clinical pharmacokinetics of the CD19 receptor-directed tyrosine kinase inhibitor B43-Genistein in patients with B-lineage lymphoid malignancies.
Chen CL; Levine A; Rao A; O'Neill K; Messinger Y; Myers DE; Goldman F; Hurvitz C; Casper JT; Uckun FM
J Clin Pharmacol; 1999 Dec; 39(12):1248-55. PubMed ID: 10586390
[TBL] [Abstract][Full Text] [Related]
30. Aberrant expression of aldehyde dehydrogenase 1A (ALDH1A) subfamily genes in acute lymphoblastic leukaemia is a common feature of T-lineage tumours.
Longville BA; Anderson D; Welch MD; Kees UR; Greene WK
Br J Haematol; 2015 Jan; 168(2):246-57. PubMed ID: 25208926
[TBL] [Abstract][Full Text] [Related]
31. Nanomedicines in B cell-targeting therapies.
Wang J; Yang J; Kopeček J
Acta Biomater; 2022 Jan; 137():1-19. PubMed ID: 34687954
[TBL] [Abstract][Full Text] [Related]
32. Identification and targeting of CD22ΔE12 as a molecular RNAi target to overcome drug resistance in high-risk B-lineage leukemias and lymphomas.
Uckun FM; Qazi S
Cancer Drug Resist; 2018; 1():30-47. PubMed ID: 31788667
[TBL] [Abstract][Full Text] [Related]
33. B cell checkpoints in autoimmune rheumatic diseases.
Rubin SJS; Bloom MS; Robinson WH
Nat Rev Rheumatol; 2019 May; 15(5):303-315. PubMed ID: 30967621
[TBL] [Abstract][Full Text] [Related]
34. Low Dose Total Body Irradiation Combined With Recombinant CD19-Ligand × Soluble TRAIL Fusion Protein is Highly Effective Against Radiation-Resistant B-Precursor Acute Lymphoblastic Leukemia in Mice.
Uckun FM; Myers DE; Ma H; Rose R; Qazi S
EBioMedicine; 2015 Apr; 2(4):306-316. PubMed ID: 26097891
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia.
Uckun FM; Myers DE; Qazi S; Ozer Z; Rose R; D'Cruz OJ; Ma H
J Clin Invest; 2015 Mar; 125(3):1006-18. PubMed ID: 25621496
[TBL] [Abstract][Full Text] [Related]
36. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia.
Portell CA; Wenzell CM; Advani AS
Clin Pharmacol; 2013; 5(Suppl 1):5-11. PubMed ID: 23671399
[TBL] [Abstract][Full Text] [Related]
37. Recombinant human CD19-ligand protein as a potent anti-leukaemic agent.
Uckun FM; Sun L; Qazi S; Ma H; Ozer Z
Br J Haematol; 2011 Apr; 153(1):15-23. PubMed ID: 21323891
[TBL] [Abstract][Full Text] [Related]
38. Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1.
Inaba H; Shimada K; Zhou YW; Ido M; Buck S; Yonehara S; Kaplan J; Komada Y
Int J Oncol; 2005 Aug; 27(2):573-9. PubMed ID: 16010441
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
